EU approves AbbVie's Boey for short-duration frown line treatment

The European Commission has approved Boey (trenibotulinumtoxinE), a botulinum neurotoxin serotype E developed by Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, for the temporary improvement of moderate to severe glabellar lines in adult patients across all 30 European Economic Area countries.

According to the company's press release, Boey is the first botulinum neurotoxin serotype E approved in Europe. In clinical studies, onset of effect was observed as early as eight hours after treatment, with effects lasting approximately two to three weeks before glabellar lines returned to baseline severity.

The approval is supported by data from two Phase 3 randomized, double-blind, placebo-controlled trials enrolling 725 patients treated with Boey 700 units or placebo. The co-primary efficacy measure was the percentage of patients achieving a two-grade or greater improvement in glabellar line severity at day seven, assessed by both investigators and patients using a four-point Facial Wrinkle Scale. Reported adverse drug reactions included eyelid ptosis (0.17%), brow ptosis (0.13%), and lateral eyebrow elevation known as Mephisto sign (0.04%).

Boey also received approval in Canada in June 2026. Allergan Aesthetics said it is preparing to launch the product across Europe and will provide healthcare professionals with education and training on its use.

The European Commission decision follows the centralized procedure, making the approval applicable across all EEA member states. AbbVie noted that Botox Cosmetic, known as Vistabel or Vistabex in the EU, is the only neurotoxin clinically tested for safety following treatment with Boey.

You May Also Be Interested In

• Abbvie (ABBV) PT Raised to $282 at Canaccord
• Ardent Health logs 1 million patient visits using ambient AI tool
• Klondike Gold completes Phase 1 drilling, reports 176 oz gold royalty